Cargando…

A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer

Bladder cancer, one of the most prevalent malignant cancers, has high rate of recurrence and metastasis. Owing to genomic instability and high-level heterogeneity of bladder cancer, chemotherapy and immunotherapy drugs sensitivity and lack of prognostic markers, the prognosis of bladder cancer is un...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zeyi, Huang, Zhengnan, Cao, Xiangqian, Zhang, Fang, Cai, Jinming, Tang, Pengfei, Yang, Chenkai, Li, Shengzhou, Yu, Dong, Yan, Yilin, Shen, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883845/
https://www.ncbi.nlm.nih.gov/pubmed/36709279
http://dx.doi.org/10.1186/s12894-023-01175-z
_version_ 1784879592457109504
author Wang, Zeyi
Huang, Zhengnan
Cao, Xiangqian
Zhang, Fang
Cai, Jinming
Tang, Pengfei
Yang, Chenkai
Li, Shengzhou
Yu, Dong
Yan, Yilin
Shen, Bing
author_facet Wang, Zeyi
Huang, Zhengnan
Cao, Xiangqian
Zhang, Fang
Cai, Jinming
Tang, Pengfei
Yang, Chenkai
Li, Shengzhou
Yu, Dong
Yan, Yilin
Shen, Bing
author_sort Wang, Zeyi
collection PubMed
description Bladder cancer, one of the most prevalent malignant cancers, has high rate of recurrence and metastasis. Owing to genomic instability and high-level heterogeneity of bladder cancer, chemotherapy and immunotherapy drugs sensitivity and lack of prognostic markers, the prognosis of bladder cancer is unclear. Necroptosis is a programmed modality of necrotic cell death in a caspase-independent form. Despite the fact that necroptosis plays a critical role in tumor growth, cancer metastasis, and cancer patient prognosis, necroptosis-related gene sets have rarely been studied in bladder cancer. As a result, the development of new necroptosis-related prognostic indicators for bladder cancer patients is critical. Herein, we assessed the necroptosis landscape of bladder cancer patients from The Cancer Genome Atlas database and classified them into two unique necroptosis-related patterns, using the consensus clustering. Then, using five prognosis-related genes, we constructed a prognostic model (risk score), which contained 5 genes (ANXA1, DOK7, FKBP10, MAP1B and SPOCD1). And a nomogram model was also developed to offer the clinic with a more useful prognostic indicator. We found that risk score was significantly associated with clinicopathological characteristics, TIME, and tumor mutation burden in patients with bladder cancer. Moreover, risk score was a valid guide for immunotherapy, chemotherapy, and targeted drugs. In our study, DOK7 was chosen to further verify our prognosis model, and functional assays indicated that knockdown the expression of DOK7 could prompt bladder cancer proliferation and migration. Our work demonstrated the potential role of prognostic model based on necroptosis genes in the prognosis, immune landscape and response efficacy of immunotherapy of bladder cancer.
format Online
Article
Text
id pubmed-9883845
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98838452023-01-29 A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer Wang, Zeyi Huang, Zhengnan Cao, Xiangqian Zhang, Fang Cai, Jinming Tang, Pengfei Yang, Chenkai Li, Shengzhou Yu, Dong Yan, Yilin Shen, Bing BMC Urol Research Bladder cancer, one of the most prevalent malignant cancers, has high rate of recurrence and metastasis. Owing to genomic instability and high-level heterogeneity of bladder cancer, chemotherapy and immunotherapy drugs sensitivity and lack of prognostic markers, the prognosis of bladder cancer is unclear. Necroptosis is a programmed modality of necrotic cell death in a caspase-independent form. Despite the fact that necroptosis plays a critical role in tumor growth, cancer metastasis, and cancer patient prognosis, necroptosis-related gene sets have rarely been studied in bladder cancer. As a result, the development of new necroptosis-related prognostic indicators for bladder cancer patients is critical. Herein, we assessed the necroptosis landscape of bladder cancer patients from The Cancer Genome Atlas database and classified them into two unique necroptosis-related patterns, using the consensus clustering. Then, using five prognosis-related genes, we constructed a prognostic model (risk score), which contained 5 genes (ANXA1, DOK7, FKBP10, MAP1B and SPOCD1). And a nomogram model was also developed to offer the clinic with a more useful prognostic indicator. We found that risk score was significantly associated with clinicopathological characteristics, TIME, and tumor mutation burden in patients with bladder cancer. Moreover, risk score was a valid guide for immunotherapy, chemotherapy, and targeted drugs. In our study, DOK7 was chosen to further verify our prognosis model, and functional assays indicated that knockdown the expression of DOK7 could prompt bladder cancer proliferation and migration. Our work demonstrated the potential role of prognostic model based on necroptosis genes in the prognosis, immune landscape and response efficacy of immunotherapy of bladder cancer. BioMed Central 2023-01-28 /pmc/articles/PMC9883845/ /pubmed/36709279 http://dx.doi.org/10.1186/s12894-023-01175-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Zeyi
Huang, Zhengnan
Cao, Xiangqian
Zhang, Fang
Cai, Jinming
Tang, Pengfei
Yang, Chenkai
Li, Shengzhou
Yu, Dong
Yan, Yilin
Shen, Bing
A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer
title A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer
title_full A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer
title_fullStr A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer
title_full_unstemmed A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer
title_short A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer
title_sort prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883845/
https://www.ncbi.nlm.nih.gov/pubmed/36709279
http://dx.doi.org/10.1186/s12894-023-01175-z
work_keys_str_mv AT wangzeyi aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT huangzhengnan aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT caoxiangqian aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT zhangfang aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT caijinming aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT tangpengfei aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT yangchenkai aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT lishengzhou aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT yudong aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT yanyilin aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT shenbing aprognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT wangzeyi prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT huangzhengnan prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT caoxiangqian prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT zhangfang prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT caijinming prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT tangpengfei prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT yangchenkai prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT lishengzhou prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT yudong prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT yanyilin prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer
AT shenbing prognosticmodelbasedonnecroptosisrelatedgenesforprognosisandtherapyinbladdercancer